

b.) Amendment to the Claims:

1. (Currently Amended) A method for stabilizing an antibody in a solution, which comprises adding glycine and citric acid to the antibody in said solution.
2. (Currently Amended) The method according to Claim 1, wherein the method of stabilizing ~~an antibody is suppression of the~~ suppresses formation of a soluble association and a chemically degraded product of the antibody in a the solution.
3. (Currently Amended) A method for suppressing the formation of a soluble association of an antibody in a solution, which comprises adding glycine to the antibody in said solution.
4. (Currently Amended) A method for suppressing the formation of a chemically degraded product of an antibody in a solution, which comprises adding citric acid to the antibody in said solution.
5. (Currently Amended) The method according to any one of Claims 1 to 4, wherein concentration of the antibody ~~is at~~ in said solution is from 0.01 to 150 mg/mL.

6. (Currently Amended) The method according to any one of Claims 1 to 3, wherein concentration of ~~the glycine is at~~ glycine in said solution is from 10 to 30 mg/mL.

7. (Currently Amended) The method according to any one of Claims 1, 2 and 4, wherein concentration of ~~the citric acid is at~~ citric acid in said solution is from 0.1 to 50 mmol/L.

8. (Currently Amended) The method according to ~~any one of Claims 1 to 7,~~ Claim 2, wherein the concentration of the antibody in said solution is 0.01 to 150 mg/mL, the concentration of glycine in said solution is 10 to 30 mg/mL and the concentration of citric acid in said solution is 0.1 to 50 mg/mL, said solution further comprising a nonionic surfactant.

9. (Currently Amended) The method according to ~~any one of Claims 1 to 8~~ Claim 8, wherein the pH of the solution is within the range of 4 to 7.

10. (Currently Amended) The method according to ~~any one of Claims 1 to 9~~ Claim 9, wherein the antibody is a humanized antibody or a human antibody.

11. (Currently Amended) The method according to ~~any one of Claims 1 to 10~~ Claim 10, wherein the antibody is ~~any one of antibodies~~ an antibody to ganglioside GD3 and ~~antibodies to CC chemokine receptor 4 (hereinafter referred to as CCR4)~~ or an antibody to CCR4.

12. (Currently Amended) A solution-type antibody preparation ~~in which formation of a soluble association of the antibody is suppressed,~~ comprising glycine and the antibody, and an effective amount of glycine to suppress formation of a soluble association of said antibody.

13. (Currently Amended) A solution-type antibody preparation ~~in which formation of a chemically degraded product of the antibody is suppressed,~~ comprising ~~citric acid~~ and the antibody, and an effective amount of citric acid to suppress formation of a chemically degraded product of said antibody.

14. (Currently Amended) A solution-type antibody preparation ~~in which formation of a soluble association, a chemically degraded product and an insoluble aggregate of the antibody are suppressed,~~ comprising ~~glycine, citric acid~~ and the antibody,

and an effective amount of glycine and citric acid to suppress formation of a soluble solution, a chemically degraded product and an insoluble aggregate of the antibody.

15. (Currently Amended) The preparation according to any one of Claims 12 to 14, wherein the antibody concentration is at 0.01 to 150 mg/mL.

16. (Currently Amended) The preparation according to ~~any one of Claims 12, 14 and 15~~ Claim 15, wherein the glycine concentration is at 10 to 30 mg/mL.

17. (Currently Amended) The preparation according to ~~any one of Claims 13 to 15~~ Claim 15, wherein the citric acid concentration is at 0.1 to 50 mmol/L.

18. (Currently Amended) The preparation according to ~~any one of Claims 12 to 17~~ Claim 16, wherein the citric acid concentration is 0.1 to 50 mmol/L, and further comprising a nonionic surfactant.

19. (Currently Amended) The preparation according to ~~any one of Claims 12 to 18~~ Claim 18, wherein the pH of the solution is ~~in the range of~~ from 4 to 7.

20. (Currently Amended) The preparation according to ~~any one of Claims 12 to 19~~ Claim 19, wherein the antibody is a humanized antibody or a human antibody.

21. The preparation according to ~~any one of Claims 12 to 20~~ Claim 20, wherein the antibody is ~~any one of antibodies~~ an antibody to ganglioside GD3 ~~and antibodies~~ or antibody to CCR4.

Claims 22-25 (Cancelled).